About

A de-risked commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®

At a glance

Shield is a de-risked commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs.

Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of Iron Deficiency with or without anaemia in adult patients which has exclusive IP rights until the mid-2030’s.

CEO & Founder

Carl Sterritt

Over the last few years Shield has transformed itself from a development-focused and private company into a publicly listed, commercially-stage, international specialty pharmaceutical company focused on providing patients and prescribers with novel products that provide solutions to unmet medical needs so we can deliver value to our shareholders.

What sets us apart

  • Lead product Feraccru®

    Currently approved in the European Union and Switzerland, Feraccru® offers a number of important advantages compared to current standards of care for Iron Deficiency with or without anaemia. Feraccru® is commercially available in the European Union and actively marketed by Norgine B.V. and AOP with more patients than ever being treated.

  • Large market opportunities with unmet needs

    In Europe it is estimated that there are more than 40 million people with Iron Deficiency with or without anaemia, representing a significant commercial opportunity for Feraccru®.

  • Experienced management team with extensive expertise

    The skilled senior management team and board of directors provide strong leadership for the Company’s future growth.

  • Strong intellectual property protection

    The Group’s assets are supported by a suite of robust intellectual property rights including key patents in major markets. The Group’s marketed product, Feraccru®, for the treatment of Iron Deficiency with or without anaemia in adults and has exclusive IP rights until the mid-2030’s.

  • Investment Case - STX Fact Sheet

    Read more about the Group’s strong investment case here